This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.
CVD is especially prevalent in the Medicare-aged population, affecting more than 75 percent of those aged 60-79 and more than 90 percent of those aged 80 and over. Eighty percent of heart attacks and strokes are preventable. Yet, CVD remains the leading cause of death in the U.S., Yet, CVD remains the leading cause of death in the U.S.,
The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy. The company recently announced it has received CMS approval for Medicare coverage during the DRAIN-HF pivotal trial.
The company’s advanced non-invasive computed tomography (CT) imaging technology enables comprehensive phenotyping of coronary artery disease, grounded in scientific research based on millions of medical images. We’re proud to be a part of Cleerly’s journey. This is what good software can do in the world!"
15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S.
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
milla1cf Tue, 04/23/2024 - 16:03 April 23, 2024 — CDL Nuclear Technologies , a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer. CDL provides this service in compliance with all healthcare regulations.
Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries.
The use of fractional flow reserve by CT per 100 000 Medicare enrollees increased by >16-fold from 2018 (the first year covered) to 2022, and cardiac amyloidosis pyrophosphate scintigraphy studies increased 4-fold from 2011 to 2022 (0.17% to 0.68%). of cardiac testing use in 2011 and 67.7% to 1.7%), stress echocardiography (3.6%
CPT codes are widely used by government payers, including Medicare and Medicaid, and commercial insurance companies to identify healthcare services and procedures for reimbursement. In accordance with the AMA semi-annual early release schedule, the new codes will be effective January 1st, 2025 and published in the 2025 CPT Code book.
The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C. Having access to a patient’s whole coronary picture, with both quantified plaque and physiology, is a game changer as a clinician. F.A.C.C. “The For more information: www.heartflow.com References: 1.
1 To qualify for a Breakthrough Device Designation, a device technology must address an unmet need and show that it has the potential to provide for more effective treatment of life-threatening diseases or irreversibly debilitating conditions. CLTI is associated with high rates of amputation and mortality as well as high care costs.1
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. 3 “We very much appreciate FDA’s breakthrough designation recognition of the bioadaptor technology,” continued Sirhan. Food and Drug Administration (FDA). of the U.S.
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. ,
Computed Tomography (CT) continues to be a rapidly evolving technology with many new advancements, as displayed and discussed at the Radiological Society of North America109th Scientific Assembly and Annual Meeting (RSNA23). As a whole, the computed tomography market size in the US in 2024 is estimated to be $2.38 Halpern, MD, and Vijay M.
The linkage also would allow registries to continue providing critical information for approval and coverage of innovative medical interventions and preserve the government’s authority to authorize Medicare Coverage with Evidence Development (CED). Download the PDF version Advocacy Quality Improvement Technology
The Office of the National Coordinator for Health Information Technology (ONC) released on July 10 the Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability (HTI-2) proposed rule, building on the HTI-1 final rule released in 2023 and additional information blocking rules released (..)
Consequently, Philips is well positioned to support CVI treatment by offering a robust portfolio of medical technology that includes both intravascular ultrasound and a differentiated venous stenting system.” Utilization of and Outcomes Associated with Intravascular Ultrasound during Deep Venous Stent Placement among Medicare Beneficiaries.
2-4 HeartFlow’s non-invasive FFR CT technology has emerged as a leading frontline strategy for accurately diagnosing hemodynamically significant coronary lesions in patients suspected of having CAD. Longitudinal assessment of safety of FEMOROPOPLITEAL endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries.”
Established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) , the MIPS Program is pivotal in determining Medicare payment adjustments for healthcare practices. What is MIPS?
GLP-1s Are So Hot Right Now – In the year since ACC 2023, GLP-1s went from a weight loss and diabetes drug that “might” have cardiovascular benefits to becoming a promising (and Medicare-covered) option for CV event reduction.
In January 2024, the Centers for Medicare and Medicaid Services (CMS) began requiring health care organizations to screen for five social factors: Food insecurity Interpersonal safety Housing insecurity Transportation Utilities The purpose of these screenings is to encourage engagement of community-based organizations with resources to address SDOH.
The data was presented today by Amish Raval , MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.
The development has urged us to integrate the latest Artificial Intelligence with the healthcare system, including Cardiac Medicare. By harnessing the power of the latest technology, healthcare providers can enhance diagnostics, treatment planning, and patient care. What is Artificial Intelligence?
3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives. With more than 500 peer-reviewed publications, the HeartFlow FFR CT Analysis remains unparalleled in precision coronary care, as supported by the ACC/AHA Chest Pain Guidelines, to improve treatment plans and outcomes.
Andrea Fletcher , Chief Digital Strategy Officer and Director of the Digital Service at Centers for Medicare and Medicaid Services ( CMS ) will present, “ Teaching the Elephant to Dance: Digital Transformation in the United States ” on March 13 in an afternoon education session.
Introduction:This study evaluates the outcomes of a survivor-centric, navigator-driven, technology-enabled platform supporting survivors (SS) and care partners(CP) in post-stroke recovery.
In late 2023, CMS released the 2024 Medicare Physician Fee Schedule (MPFS) Final Rule, ushering in key policy changes for the Quality Payment Program (QPP). Benchmarks for the 2023 performance period for eCQMs, MIPS CQMs, QCDR measures, and Medicare Part B claims are based on actual performance data submitted for the 2021 performance period.
1 For the care of patients with CIEDs on RM, manufacturers should include key stakeholders in the design and development of technologies for RM. 1 In patients with CIEDs on RM, the manufacturer should provide an RM system that is reliable, safe, accurate, and meets the needs of the patient.
Cardiac implantable devices are sophisticated technology that provide both therapy and diagnostics for patients with irregular heart rhythms. With effective management and use, RPM can provide clinicians with the tools to improve patient outcomes and deliver better quality care. What is Cardiac Remote Patient Monitoring Software ?
I learned about the complexities of health insurance – and after several years, I transitioned to the Medicare & Retirement Clinical value team where we worked to reduce the cost of United’s Medicare Advantage plans. Technology in healthcare is a double-edged sword.
Ensure all Medicare Administrative Contractors (MACs) and health plans are accepting paper claims. Encourage the health information technology community to postpone user fees. Physicians need an up-to-date database that compiles all the payers that are offering advance payments to physicians.
Since 1923, technologies have emerged for insulin production, delivery of insulin, and blood glucose monitoring, including insulin pens, insulin pumps, lancets, test strips, and continuous glucose monitoring (CGM)—for those who can afford it. However, we continue to see incremental improvements in the field of insulin therapy.
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)
13, 2025 Medtronic plc recently announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.
13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.
Additionally, the company announced that the Centers for Medicare & Medicaid Services (CMS) has granted Category B approval for the investigational device exemption (IDE) study, ensuring Medicare coverage for the device, related and routine items, and services for the ELITE-BTK trial. Commenting on the announcements, Christopher M.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content